Latest for Porphyria Cutanea Tarda
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
- Trial sitesA new site opened in Houston, Texas for Longitudinal Study of the PorphyriasClinicalTrials.gov
More about Porphyria Cutanea Tarda
Type I PCT (80% of cases) is acquired without UROD gene mutations, usually triggered by hepatitis C infection, HIV infection, alcohol consumption, estrogen use, iron overload, or other factors that impair hepatic UROD enzyme activity. Types II and III have underlying UROD mutations with type II being familial (inherited heterozygously) and type III sporadic due to somatic mutations or hemizygous inheritance patterns.
Keep reading about Porphyria Cutanea Tarda
The condition presents with photosensitive blistering on dorsal hands, forearms, face, and other sun-exposed areas triggered by minimal sun exposure. Blisters develop readily and heal with scarring, milia formation, and atrophic changes. Hyperpigmentation occurs with associated hypertrichosis and scleroderma-like skin changes on dorsal hands. Photofluorescence of urine under Wood's lamp reveals elevated porphyrins characteristic of the disease.
Hepatic involvement ranges from mild transaminitis to cirrhosis. Malignancy risk, particularly hepatocellular carcinoma, is increased in patients with underlying hepatitis C or cirrhosis.
What are the symptoms of Porphyria Cutanea Tarda?
These are common symptoms of Porphyria Cutanea Tarda, and how strong they are varies from person to person.
- Fragile skin with blistering on sun-exposed areas
- Hyperpigmentation and hypopigmentation
- Hypertrichosis
- Photosensitivity
- Scarring and milia on hands
- Liver disease in some cases
Who gets Porphyria Cutanea Tarda?
Type 1 PCT manifests typically in middle age (40-60 years) though can occur from adolescence to elderly individuals. Males affected more frequently than females overall, though gender distribution varies by type and triggering factors.
Estrogen-related cases predominantly affect women receiving hormone replacement therapy or oral contraceptives. More common in individuals of European descent though reported across all populations. Strong geographic variation with higher prevalence in Mediterranean regions and parts of Eastern Europe.
Hepatitis C coinfection significantly increases prevalence in certain populations. Alcohol abuse and HIV infection increase susceptibility across all ethnic groups. Genetic factors in types II and III show autosomal dominant inheritance with reduced penetrance.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
How to get help paying for Porphyria Cutanea Tarda treatment
Charity funds and drugmaker programs for Porphyria Cutanea Tarda, checked at the source.
- From a charity · HealthWell FoundationPorphyrias fundOpen
Pays for: Copays, premiums or other treatment costs.
- From a charity · The Assistance FundPorphyria fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for Porphyria Cutanea Tarda
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Porphyria Cutanea Tarda resources
Reputable organizations and medical references for learning more about Porphyria Cutanea Tarda, including disease registries, foundation resources, and clinical guidelines.